Table 2 Clinical trials of identified mitochondrial inhibitors
From: Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Inhibitor | Target | Cancer type | ClinicalTrials.gov Identifier | Status |
|---|---|---|---|---|
Metformin | CI | Breast cancer | NCT04559308 | Recruiting |
| Â | Â | Breast cancer | NCT00897884 | Completed |
| Â | Â | Rectal cancer | NCT02437656 | Completed |
| Â | Â | etc. | Â | Â |
VLX600 | ETC | Refractory cancer | NCT02222363 | Terminated |
Fenretinide | CIV | Advanced or metastatic hormone refractory prostate cancer | NCT00077402 | Completed |
| Â | Â | Lung cancer | NCT00009971 | Completed |
| Â | Â | Bladder cancer | NCT00004154 | Completed |
| Â | Â | etc. | Â | Â |
Resveratrol | CIII | Colon cancer | NCT00256334 | Completed |
| Â | Â | Liver cancer | NCT00433576 | Completed |
| Â | Â | Breast cancer | NCT03482401 | Completed |
| Â | Â | etc. | Â | Â |
Tigecycline | Mitochondrial ribosomal machinery | Acute myeloid leukemia | NCT01332786 | Completed |
Gamitrinib | Mitochondrial chaperone proteins, such as TRAP-1 and HSP-90 | Lymphoma, advanced solid tumor | NCT04827810 | Recruiting |
CPI-613 | TCA cycle, PDH | Biliary tract cancer | NCT04203160 | Recruiting |
| Â | Â | Advanced hematologic malignancies | NCT01034475 | Completed |
| Â | Â | Recurrent small cell lung cancer | NCT01931787 | Completed |
| Â | Â | etc. | Â | Â |
Dichloroacetate | PDK | Head and neck cancer | NCT01163487 | Completed |
| Â | Â | Squamous cell carcinoma of the head and neck | NCT01386632 | Completed |
| Â | Â | etc. | Â | Â |
IACS-010759 | CI, TCA cycle | Advanced malignant solid neoplasm; Anatomic stage IIIA breast cancer | NCT03291938 | Completed |
| Â | Â | Recurrent acute myeloid leukemia | NCT02882321 | Active, not recruiting |
| Â | Â | etc. | Â | Â |
Leflunomide | DHODH | Breast neoplasms | NCT03709446 | Recruiting |
| Â | Â | Prostate cancer | NCT00004071 | Completed |
| Â | Â | Brain and central nervous system tumors | NCT00003775 | Completed |
| Â | Â | etc. | Â | Â |
ONC201 | OXPHOS | Endometrial cancer recurrent | NCT03485729 | Recruiting |
| Â | Â | Triple-negative breast cancer; endometrial cancer; hormone receptor positive, HER2 negative breast cancer | NCT03394027 | Completed |
| Â | Â | Recurrent neuroendocrine tumor; metastatic neuroendocrine tumor | NCT03034200 | Active, not recruiting |
| Â | Â | etc. | Â | Â |
Tamoxifen | ETC | Breast cancer | NCT00286117 | Completed |
| Â | Â | Estrogen receptor positive breast cancer | NCT02988986 | Completed |
| Â | Â | Bladder cancer | NCT02197897 | Completed |
ME-344 | ETC | Breast cancer; human epidermal growth factor 2 negative carcinoma of breast; early-stage breast carcinoma | NCT02806817 | Completed |
| Â | Â | etc. | Â | Â |
Gossypol | Bcl-2 family proteins | Extensive stage small cell lung cancer; Recurrent small cell lung cancer | NC T00666666 | Completed |
| Â | Â | etc. | Â | Â |
Lometrexol | SHMT2 | Lung cancer; | NCT00033722 | Unknown |
| Â | Â | Unspecified adult solid tumor, protocol specific | NCT00024310 | Unknown |